R207910
Jump to navigation
Jump to search
WikiDoc Resources for R207910 |
Articles |
---|
Most recent articles on R207910 |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on R207910 at Clinical Trials.gov Clinical Trials on R207910 at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on R207910
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating R207910 Risk calculators and risk factors for R207910
|
Healthcare Provider Resources |
Causes & Risk Factors for R207910 |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
R207910 is an experimental anti-tuberculosis drug.[1]
References
- ↑ de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K (2007). "A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910". Proteins. 67 (4): 971–80. doi:10.1002/prot.21376. PMID 17387738.